Abstract P4-01-06: Elacestrant (RAD1901) inhibits growth of ex vivo cultured circulating tumor cells derived from hormone receptor-positive metastatic breast cancer (mBC) patients including those harboring ESR1 mutations
Taronish D. Dubash(Harvard University), Shyamala Maheswaran(Massachusetts General Hospital), David T. Ting(Massachusetts General Hospital), John Iafrate(Harvard University), Aditya Bardia(UCLA Health), Daniel A. Haber(Howard Hughes Medical Institute), Brittany A. Reeves(Harvard University), Ben S. Wittner(Broad Institute), Teeru Bihani(Lava Therapeutics (Netherlands)), Mehmet Toner(Center for Cancer Research), Brian Chirn(Harvard University), Hitisha Patel(Radius Health (United States)), Annamária Szabolcs(Harvard University)
Cited by 2